Hematopoietic growth factors, version 1.2020: Featured updates to the NCCN guidelines

Pamela Sue Becker; Elizabeth A. Griffiths; Laura M. Alwan; Kimo Bachiashvili; Anna Brown; Rita Cool; Peter Curtin; Shira Dinner; Ivana Gojo; Ashley Hicks; Avyakta Kallam; Wajih Zaheer Kidwai; Dwight D. Kloth; Eric H. Kraut; Daniel Landsburg; Gary H. Lyman; Ryan Miller; Sudipto Mukherjee; Shiven Patel; Lia E. Perez; Adam Poust; Raajit Rampal; Rachel Rosovsky; Vivek Roy; Hope S. Rugo; Sepideh Shayani; Sumithira Vasu; Martha Wadleigh; Kelly Westbrook; Peter Westervelt; Jennifer Burns; Jennifer Keller; Lenora A. Pluchino

doi:10.6004/jnccn.2020.0002

Hematopoietic growth factors, version 1.2020: Featured updates to the NCCN guidelines

Pamela Sue Becker, Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Shira Dinner, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Ryan Miller, Sudipto Mukherjee, Shiven Patel, Lia E. PerezAdam Poust, Raajit Rampal, Rachel Rosovsky, Vivek Roy, Hope S. Rugo, Sepideh Shayani, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Jennifer Burns, Jennifer Keller, Lenora A. Pluchino

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

84 Scopus citations

Abstract

Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.

Original language	English (US)
Pages (from-to)	12-22
Number of pages	11
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	18
Issue number	1
DOIs	https://doi.org/10.6004/jnccn.2020.0002
State	Published - 2020

Funding

This activity is supported by educational grants from AstraZeneca; Celgene Corporation; Coherus BioSciences; Genentech, a member of the Roche Group; and TESARO, a GSK Company. This activity is supported in part by an educational grant from Bayer Healthcare Pharmaceuticals. This activity is supported by an independent medical education grant from Bristol-Myers Squibb. This activity is supported by a medical education grant from Exelixis, Inc. This activity is supported by an independent educational grant from Merck & Co., Inc.

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.6004/jnccn.2020.0002

Cite this

Becker, P. S., Griffiths, E. A., Alwan, L. M., Bachiashvili, K., Brown, A., Cool, R., Curtin, P., Dinner, S., Gojo, I., Hicks, A., Kallam, A., Kidwai, W. Z., Kloth, D. D., Kraut, E. H., Landsburg, D., Lyman, G. H., Miller, R., Mukherjee, S., Patel, S., ... Pluchino, L. A. (2020). Hematopoietic growth factors, version 1.2020: Featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 18(1), 12-22. https://doi.org/10.6004/jnccn.2020.0002

@article{6be8e01ef4b0406b969f9c0100a24a0f,

title = "Hematopoietic growth factors, version 1.2020: Featured updates to the NCCN guidelines",

abstract = "Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.",

author = "Becker, {Pamela Sue} and Griffiths, {Elizabeth A.} and Alwan, {Laura M.} and Kimo Bachiashvili and Anna Brown and Rita Cool and Peter Curtin and Shira Dinner and Ivana Gojo and Ashley Hicks and Avyakta Kallam and Kidwai, {Wajih Zaheer} and Kloth, {Dwight D.} and Kraut, {Eric H.} and Daniel Landsburg and Lyman, {Gary H.} and Ryan Miller and Sudipto Mukherjee and Shiven Patel and Perez, {Lia E.} and Adam Poust and Raajit Rampal and Rachel Rosovsky and Vivek Roy and Rugo, {Hope S.} and Sepideh Shayani and Sumithira Vasu and Martha Wadleigh and Kelly Westbrook and Peter Westervelt and Jennifer Burns and Jennifer Keller and Pluchino, {Lenora A.}",

note = "Publisher Copyright: {\textcopyright} National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.",

year = "2020",

doi = "10.6004/jnccn.2020.0002",

language = "English (US)",

volume = "18",

pages = "12--22",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Harborside Press",

number = "1",

}

Becker, PS, Griffiths, EA, Alwan, LM, Bachiashvili, K, Brown, A, Cool, R, Curtin, P, Dinner, S, Gojo, I, Hicks, A, Kallam, A, Kidwai, WZ, Kloth, DD, Kraut, EH, Landsburg, D, Lyman, GH, Miller, R, Mukherjee, S, Patel, S, Perez, LE, Poust, A, Rampal, R, Rosovsky, R, Roy, V, Rugo, HS, Shayani, S, Vasu, S, Wadleigh, M, Westbrook, K, Westervelt, P, Burns, J, Keller, J & Pluchino, LA 2020, 'Hematopoietic growth factors, version 1.2020: Featured updates to the NCCN guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 18, no. 1, pp. 12-22. https://doi.org/10.6004/jnccn.2020.0002

TY - JOUR

T1 - Hematopoietic growth factors, version 1.2020

T2 - Featured updates to the NCCN guidelines

AU - Becker, Pamela Sue

AU - Griffiths, Elizabeth A.

AU - Alwan, Laura M.

AU - Bachiashvili, Kimo

AU - Brown, Anna

AU - Cool, Rita

AU - Curtin, Peter

AU - Dinner, Shira

AU - Gojo, Ivana

AU - Hicks, Ashley

AU - Kallam, Avyakta

AU - Kidwai, Wajih Zaheer

AU - Kloth, Dwight D.

AU - Kraut, Eric H.

AU - Landsburg, Daniel

AU - Lyman, Gary H.

AU - Miller, Ryan

AU - Mukherjee, Sudipto

AU - Patel, Shiven

AU - Perez, Lia E.

AU - Poust, Adam

AU - Rampal, Raajit

AU - Rosovsky, Rachel

AU - Roy, Vivek

AU - Rugo, Hope S.

AU - Shayani, Sepideh

AU - Vasu, Sumithira

AU - Wadleigh, Martha

AU - Westbrook, Kelly

AU - Westervelt, Peter

AU - Burns, Jennifer

AU - Keller, Jennifer

AU - Pluchino, Lenora A.

N1 - Publisher Copyright: © National Comprehensive Cancer Network, Inc. 2020. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

PY - 2020

Y1 - 2020

N2 - Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.

AB - Management of febrile neutropenia (FN) is an integral part of supportive care for patients undergoing cancer treatment. The NCCN Guidelines for Hematopoietic Growth Factors provide suggestions for appropriate evaluation, risk determination, prophylaxis, and management of FN. These NCCN Guidelines are intended to guide clinicians in the appropriate use of growth factors for select patients undergoing treatment of nonmyeloid malignancies. These NCCN Guidelines Insights highlight important updates to the NCCN Guidelines regarding the incorporation of newly FDA-approved granulocyte-colony stimulating factor biosimilars for the prevention and treatment of FN.

UR - http://www.scopus.com/inward/record.url?scp=85077705517&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077705517&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2020.0002

DO - 10.6004/jnccn.2020.0002

M3 - Article

C2 - 31910384

AN - SCOPUS:85077705517

SN - 1540-1405

VL - 18

SP - 12

EP - 22

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 1

ER -

Hematopoietic growth factors, version 1.2020: Featured updates to the NCCN guidelines

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this